Blog

Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO

Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced that Robert Jacks has been appointed President & CEO. Mr. Jacks brings to Indalo 18 years of experience in biopharmaceutical product development, corporate strategy, business development, fundraising, commercial analysis, finance, and operations. He joins a seasoned leadership team with a history of scientific and business success. Chief Medical Officer Bill Bradford, MD, PhD, and Chief Scientific Officer Scott D. Seiwert, PhD, were senior leaders at Intermune, where they were instrumental in the development and approval of Esbriet® (pirfenidone) prior to the acquisition of the company by Roche in 2014.

Atlas Venture and F-Prime Capital co-led the company’s $26 million Series A financing. BioGenerator, MTC, and iSelect Fund are among the company’s other investors.

Indalo’s lead drug candidate, IDL-2965, which is scheduled to enter the clinic in early 2019, is an oral, selective, RGD-binding integrin antagonist that inhibits the activation of TGF-β (a fibrogenic growth factor) as well as the ability of stiff extracellular matrix to promote fibroblast migration and survival. IDL-2965 displays potent antifibrotic efficacy at low once-daily doses across multiple models of disease in vital organ systems, including the liver, lung, and kidney. Indalo has completed a rigorous set of GLP toxicology and safety-pharmacology studies with IDL-2965 in preparation for human studies and has designed an efficient and adaptive Phase 1 program that enables assessment of safety, PK, and biomarker-based proof of mechanism in NASH and IPF patients.

“I’m thrilled to join Indalo at this critical point in its evolution to a clinical-stage biotechnology company,” commented Mr. Jacks. “Indalo’s differentiated approach, which targets key RGD-binding integrins on fibroblasts and epithelial cells to inhibit multiple processes of pathologic fibrosis, has the potential to transform the lives of millions of patients suffering from serious fibrotic diseases.”

Click here to read the entire press release.